Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1850 of 2051 entries
View as:

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Phase: N/A Priority: Normal
NCT ID: NCT01340768 Org: User:
Start: 06/22/10 End: 09/21/11 Due: 09/21/12

Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

Phase: N/A Priority: Normal
NCT ID: NCT02387983 Org: User:
Start: 05/06/15 End: 05/02/16 Due: 05/02/17

Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

Phase: N/A Priority: Normal
NCT ID: NCT01986010 Org: User:
Start: 11/25/13 End: 03/14/17 Due: 03/14/18

Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)

Phase: N/A Priority: Normal
NCT ID: NCT01335997 Org: User:
Start: 05/01/11 End: 01/01/12 Due: 01/01/13

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

Phase: N/A Priority: Normal
NCT ID: NCT01948986 Org: User:
Start: 10/01/13 End: 10/16/14 Due: 10/16/15

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Phase: N/A Priority: Normal
NCT ID: NCT00536263 Org: User:
Start: 09/30/07 End: 11/30/09 Due: 11/30/10

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Phase: N/A Priority: Normal
NCT ID: NCT06179407 Org: User:
Start: 01/24/24 End: 10/23/24 Due: 10/23/25

Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)

Phase: N/A Priority: Normal
NCT ID: NCT00725751 Org: User:
Start: 09/30/07 End: 03/31/11 Due: 03/31/12

A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)

Phase: N/A Priority: Normal
NCT ID: NCT06821334 Org: User:
Start: 04/23/24 End: 08/09/24 Due: 08/09/25

A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)

Phase: N/A Priority: Normal
NCT ID: NCT00824616 Org: User:
Start: 01/31/09 End: 05/31/10 Due: 05/31/11

MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).

Phase: N/A Priority: Normal
NCT ID: NCT00754130 Org: User:
Start: 09/30/08 End: 10/31/08 Due: 10/31/09

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00811967 Org: User:
Start: 02/28/03 End: 05/31/06 Due: 05/31/07

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT04865289 Org: User:
Start: 10/22/19 End: 01/14/25 Due: 01/14/26

MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)

Phase: N/A Priority: Normal
NCT ID: NCT00420420 Org: User:
Start: 11/30/06 End: 08/31/08 Due: 08/31/09

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Phase: N/A Priority: Normal
NCT ID: NCT04635423 Org: User:
Start: 11/30/20 End: 08/15/25 Due: 08/15/26

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Phase: N/A Priority: Normal
NCT ID: NCT05027074 Org: User:
Start: 09/17/21 End: 02/13/25 Due: 02/13/26

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00533481 Org: User:
Start: 02/29/04 End: 12/31/04 Due: 12/31/05

Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00266812 Org: User:
Start: 03/08/05 End: 01/16/08 Due: 01/16/09

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Phase: N/A Priority: Normal
NCT ID: NCT01254643 Org: User:
Start: 01/12/11 End: 08/10/13 Due: 08/10/14

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Phase: N/A Priority: Normal
NCT ID: NCT01371604 Org: User:
Start: 07/31/11 End: 10/31/14 Due: 10/31/15

Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)

Phase: N/A Priority: Normal
NCT ID: NCT00081510 Org: User:
Start: 12/31/03 End: 05/31/09 Due: 05/31/10

Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00092469 Org: User:
Start: 03/31/02 End: 08/31/03 Due: 08/31/04

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Phase: N/A Priority: Normal
NCT ID: NCT02684292 Org: User:
Start: 05/23/16 End: 07/18/25 Due: 07/18/26

Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)

Phase: N/A Priority: Normal
NCT ID: NCT00543387 Org: User:
Start: 03/27/08 End: 04/04/11 Due: 04/04/12

Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)

Phase: N/A Priority: Normal
NCT ID: NCT02972034 Org: User:
Start: 01/13/17 End: 12/02/22 Due: 12/02/23